Related references
Note: Only part of the references are listed.AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis
J. Hercogova et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Vibeke Strand et al.
BIODRUGS (2020)
Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis
Kelly A. Reynolds et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Jinmei Su et al.
BIODRUGS (2020)
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
HoUng Kim et al.
DRUGS (2020)
Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
Erhui Zhang et al.
AAPS JOURNAL (2020)
A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
Richard Markus et al.
ADVANCES IN THERAPY (2019)
Biosimilars for the treatment of psoriasis
Lluis Puig et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial
Huji Xu et al.
LANCET RHEUMATOLOGY (2019)
Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab
B. Gorovits et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
L. Cai et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
Alan Menter et al.
DERMATOLOGY AND THERAPY (2017)
Development of biosimilars
Ahmad AL-Sabbagh et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis
Hsien-Yi Chiu et al.
ACTA DERMATO-VENEREOLOGICA (2015)
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper
Gionata Fiorino et al.
AUTOIMMUNITY REVIEWS (2014)
Prevalence of psoriasis in China: A population-based study in six cities
Xiaolan Ding et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2012)
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
Akihiko Asahina et al.
JOURNAL OF DERMATOLOGY (2010)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J. -H. Saurat et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Share Paper
